Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ambrx Biopharma Inc ADR (NY: AMAM )

N/A UNCHANGED
Last Price Updated: 7:00 PM EDT, Mar 16, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ambrx Biopharma Inc ADR

< Previous 1 2 3 4 5 6 7 8 Next >
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
From ​Ambrx Biopharma Inc.
Via Business Wire
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 reverse stock split. 
Via Benzinga
Ambrx Biopharma Stops Working On Breast Cancer Candidate, Cites Competition As The Reason
Via Benzinga
Ambrx Announces Abrupt Leadership Change, Discuses Pipeline Review
Via Benzinga
Ambrx Biopharma's ARX788 Selected For Phase 2 Adaptive Breast Cancer Trial
Via Benzinga
Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
Gainers Summit Therapeutics Inc. (NASDAQ: SMMT) shares surged 82.2% to $1.4299 after the company announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecific... 
Via Benzinga
Why MEI Pharma Shares Are Trading Lower By Around 35%; Here Are 20 Stocks Moving Premarket
Gainers Starry Group Holdings, Inc. (NYSE: STRY) shares rose 43.5% to $0.2011 in pre-market trading after dipping more than 20% on Monday. 
Via Benzinga
Earnings Scheduled For April 26, 2022
Companies Reporting Before The Bell • First American Financial (NYSE:FAF) is estimated to report quarterly loss at $0.09 per share on revenue of $46.41 million. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 64 companies achieved new lows for the year. 
Via Benzinga
Week In Review: Insilico Signs Six-Drug Discovery Deal With Sanofi Worth Up To $1.2 Billion
Insilico Medicine signed a six-drug research collaboration with Sanofi that could be worth up to $1.2 billion. Insilico will receive up to $21.5 million in upfront and target nomination fees for each... 
Via Talk Markets
Ambrx Announces NovoCodex’s Dosing of First Patient with ARX305, Ambrx’s Investigational Antibody Drug Conjugate Targeting CD70
From Ambrx
Via Business Wire
Ambrx Biopharma Inc. Appoints Daniel O’Connor as Chief Executive Officer
From Ambrx
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
  During Monday's session, 38 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 120 companies set new 52-week lows. 
Via Benzinga
Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday
Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case. 
Via Benzinga
Why Bank of America Shares Are Trading Higher? Here Are 66 Stocks Moving In Monday's Mid-Day Session
Gainers FedNat Holding Company (NASDAQ: FNHC) shares rose 78.9% to $0.93 after jumping 48% on Friday. 
Via Benzinga
Ambrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate Update
From Ambrx, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's trading, 62 companies set new 52-week lows. 
Via Benzinga
Ambrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng Tian
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of Directors
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. to Present at the H.C. Wainwright Preclinical Cancer Drug Discover Conference
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. Appoints Janet Loesberg to Board of Directors
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. to Participate in Upcoming Investor Conferences
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. Appoints Janice Lu, M.D., Ph.D., as Chief Medical Officer
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. to Present at Upcoming Investor Conferences
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. Announces Filing of Annual Report on Form 20-F
From Ambrx Biopharma Inc.
Via Business Wire
Ambrx Biopharma Inc. Reports Full Year 2021 Financial Results; Provides Corporate Update
From Ambrx, Inc.
Via Business Wire
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Ambrx Biopharma Inc. and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of ARX788 in the I-SPY 2.2 Phase 2 Adaptive Clinical Trial for Breast Cancer
From Ambrx, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.